All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2nd European CAR T Cell Meeting in Sitges, ES, the AML Global Portal was delighted to speak to Warren Hazelton, University College London, London, UK. We asked: How could nanobody-based tri-specific CAR T cells improve the treatment of AML?
Warren Hazelton explains the importance of understanding intra-tumor heterogeneity when treating patients. He talks about a new approach which aims to target up to three AML-associated antigens to overcome problems such as antigen negative escape. He also discusses the benefits of a small CAR construct
How could nanobody-based tri-specific CAR T cells improve the treatment of AML?
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox